Published in Biochim Biophys Acta on May 19, 2010
Progesterone for the Treatment of Traumatic Brain Injury III (ProTECT) | NCT00822900
Neurosteroids as regenerative agents in the brain: therapeutic implications. Nat Rev Endocrinol (2013) 0.99
Allopregnanolone restores hippocampal-dependent learning and memory and neural progenitor survival in aging 3xTgAD and nonTg mice. Neurobiol Aging (2011) 0.96
Allopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of Alzheimer's disease. PLoS One (2011) 0.95
Frontiers in therapeutic development of allopregnanolone for Alzheimer's disease and other neurological disorders. Front Cell Neurosci (2014) 0.90
The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. Korean J Urol (2014) 0.85
Neuroregenerative mechanisms of allopregnanolone in Alzheimer's disease. Front Endocrinol (Lausanne) (2012) 0.84
Allopregnanolone and neurogenesis in the nigrostriatal tract. Front Cell Neurosci (2014) 0.83
Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res (2012) 0.82
Neuroprotective actions of neurosteroids. Front Endocrinol (Lausanne) (2011) 0.82
Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. Psychopharmacology (Berl) (2014) 0.81
Allopregnanolone reinstates tyrosine hydroxylase immunoreactive neurons and motor performance in an MPTP-lesioned mouse model of Parkinson's disease. PLoS One (2012) 0.80
Glycine and GABA(A) ultra-sensitive ethanol receptors as novel tools for alcohol and brain research. Mol Pharmacol (2014) 0.78
Allopregnanolone attenuates Aβ25-35-induced neurotoxicity in PC12 cells by reducing oxidative stress. Int J Clin Exp Med (2015) 0.77
Pregnenolone sulfate as a modulator of synaptic plasticity. Psychopharmacology (Berl) (2014) 0.76
Sex and the development of Alzheimer's disease. J Neurosci Res (2017) 0.76
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A (1993) 15.04
Alzheimer's disease. Lancet (2006) 9.15
Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging (2004) 7.83
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci (2009) 3.97
Alzheimer's disease: the cholesterol connection. Nat Neurosci (2003) 2.99
ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med (2006) 2.86
Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat Med (2004) 2.71
Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol (2004) 2.57
Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int (2004) 2.47
Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit Care (2008) 2.33
Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci U S A (1998) 2.12
A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. J Clin Psychiatry (2005) 1.92
Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. J Biol Chem (2003) 1.90
Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. Exp Neurol (2004) 1.73
Cholesterol in Alzheimer's disease. Lancet Neurol (2005) 1.72
Peripheral benzodiazepine receptor in cholesterol transport and steroidogenesis. Steroids (1997) 1.69
Cholesterol and the biology of Alzheimer's disease. Neuron (2004) 1.64
The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. J Neurotrauma (2005) 1.58
Allopregnanolone and progesterone decrease cell death and cognitive deficits after a contusion of the rat pre-frontal cortex. Neuroscience (2004) 1.55
The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. J Neurosci (2005) 1.46
Rapid brain autopsy. The Joseph and Kathleen Bryan Alzheimer's Disease Research Center experience. Arch Pathol Lab Med (1997) 1.46
Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it. Proc Natl Acad Sci U S A (1992) 1.46
Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am J Pathol (2004) 1.43
Influence of APOE polymorphism on cognitive and behavioural outcome in moderate and severe traumatic brain injury. J Neurol Neurosurg Psychiatry (2006) 1.43
Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc Natl Acad Sci U S A (1996) 1.42
Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry (1998) 1.38
Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone-induced suppression. Eur J Neurosci (2002) 1.33
Progesterone synthesis and myelin formation by Schwann cells. Science (1995) 1.32
Synthesis, metabolism, and pharmacological activity of 3 alpha-hydroxy steroids which potentiate GABA-receptor-mediated chloride ion uptake in rat cerebral cortical synaptoneurosomes. J Med Chem (1990) 1.32
Allopregnanolone, a progesterone metabolite, is more effective than progesterone in reducing cortical infarct volume after transient middle cerebral artery occlusion. Ann Emerg Med (2006) 1.30
Characterization of steroid interactions with gamma-aminobutyric acid receptor-gated chloride ion channels: evidence for multiple steroid recognition sites. Mol Pharmacol (1990) 1.29
Dehydroepiandrosterone: a potential signalling molecule for neocortical organization during development. Proc Natl Acad Sci U S A (1998) 1.29
Effects of low- and high-nicotine cigarette smoking on mood states and the HPA axis in men. Neuropsychopharmacology (2005) 1.28
Allopregnanolone, a progesterone metabolite, enhances behavioral recovery and decreases neuronal loss after traumatic brain injury. Restor Neurol Neurosci (2004) 1.26
Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. J Neurosci (1996) 1.26
Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry (2001) 1.25
Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients. J Clin Endocrinol Metab (2002) 1.25
The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res (2005) 1.24
Sigma1 (sigma 1) receptor agonists and neurosteroids attenuate B25-35-amyloid peptide-induced amnesia in mice through a common mechanism. Neuroscience (1998) 1.23
Finasteride, a 5alpha-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. J Pharmacol Exp Ther (1999) 1.22
Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. J Neurochem (2009) 1.20
Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimers Res Ther (2010) 1.20
Progesterone and its metabolites increase myelin basic protein expression in organotypic slice cultures of rat cerebellum. J Neurochem (2003) 1.18
The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease. Biol Psychiatry (2006) 1.15
In socially isolated mice, the reversal of brain allopregnanolone down-regulation mediates the anti-aggressive action of fluoxetine. Proc Natl Acad Sci U S A (2003) 1.14
Microtubule-associated protein 2 (MAP2) is a neurosteroid receptor. Proc Natl Acad Sci U S A (2006) 1.13
Allopregnanolone treatment, both as a single injection or repetitively, delays demyelination and enhances survival of Niemann-Pick C mice. J Neurosci Res (2005) 1.12
Mitotic and neurogenic effects of dehydroepiandrosterone (DHEA) on human neural stem cell cultures derived from the fetal cortex. Proc Natl Acad Sci U S A (2004) 1.10
Reduced progesterone metabolites protect rat hippocampal neurones from kainic acid excitotoxicity in vivo. J Neuroendocrinol (2004) 1.10
The role of caspases in Alzheimer's disease; potential novel therapeutic opportunities. Apoptosis (2010) 1.06
Endogenous and synthetic neurosteroids in treatment of Niemann-Pick Type C disease. Brain Res Rev (2007) 1.05
Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav Pharmacol (2006) 1.04
Neuroactive steroids, negative affect, and nicotine dependence severity in male smokers. Psychopharmacology (Berl) (2006) 1.03
Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology (2006) 1.02
Dehydroepiandrosterone and allopregnanolone protect sympathoadrenal medulla cells against apoptosis via antiapoptotic Bcl-2 proteins. Proc Natl Acad Sci U S A (2004) 1.01
Apoptosis and in vitro Alzheimer disease neuronal models. Commun Integr Biol (2009) 1.00
The interplay of neurotransmitters in Alzheimer's disease. CNS Spectr (2005) 0.99
Dehydroepiandrosterone antagonizes the neurotoxic effects of corticosterone and translocation of stress-activated protein kinase 3 in hippocampal primary cultures. Neuroscience (1999) 0.99
Pregnenolone stabilizes microtubules and promotes zebrafish embryonic cell movement. Nature (2006) 0.98
Role of pregnenolone, dehydroepiandrosterone and their sulfate esters on learning and memory in cognitive aging. Brain Res Brain Res Rev (2001) 0.98
Neurosteroids as endogenous inhibitors of neuronal cell apoptosis in aging. Ann N Y Acad Sci (2006) 0.97
Neurosteroids reduce inflammation after TBI through CD55 induction. Neurosci Lett (2007) 0.97
beta-estradiol, dehydroepiandrosterone, and dehydroepiandrosterone sulfate protect against N-methyl-D-aspartate-induced neurotoxicity in rat hippocampal neurons by different mechanisms. J Pharmacol Exp Ther (2004) 0.96
The pharmacology of neurosteroidogenesis. J Steroid Biochem Mol Biol (1994) 0.96
Fluoxetine and norfluoxetine stereospecifically facilitate pentobarbital sedation by increasing neurosteroids. Proc Natl Acad Sci U S A (2004) 0.95
Modulation of GABA-gated chloride ion influx in the brain by dehydroepiandrosterone and its metabolites. Biochem Biophys Res Commun (1998) 0.94
Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy? Pharmacol Biochem Behav (2006) 0.94
Anti-seizure effects of progesterone and 3alpha,5alpha-THP in kainic acid and perforant pathway models of epilepsy. Psychoneuroendocrinology (2000) 0.94
Neurodegeneration in heterozygous Niemann-Pick type C1 (NPC1) mouse: implication of heterozygous NPC1 mutations being a risk for tauopathy. J Biol Chem (2005) 0.93
Potentiation by dehydroepiandrosterone of the neuronal response to N-methyl-D-aspartate in the CA3 region of the rat dorsal hippocampus: an effect mediated via sigma receptors. J Endocrinol (1996) 0.93
Allopregnanolone treatment delays cholesterol accumulation and reduces autophagic/lysosomal dysfunction and inflammation in Npc1-/- mouse brain. Brain Res (2009) 0.92
Progesterone and its derivatives dihydroprogesterone and tetrahydroprogesterone reduce myelin fiber morphological abnormalities and myelin fiber loss in the sciatic nerve of aged rats. Neurobiol Aging (2003) 0.91
Pregnenolone sulfate enhances long-term potentiation in CA1 in rat hippocampus slices through the modulation of N-methyl-D-aspartate receptors. J Neurosci Res (2004) 0.90
Clozapine, but not haloperidol, increases brain concentrations of neuroactive steroids in the rat. Neuropsychopharmacology (2001) 0.90
Dehydroepiandrosterone protects hippocampal neurons against neurotoxin-induced cell death: mechanism of action. Proc Soc Exp Biol Med (1999) 0.90
3alpha,5alpha-THP: a potential plasma neurosteroid biomarker in Alzheimer's disease and perhaps non-Alzheimer's dementia. Psychopharmacology (Berl) (2005) 0.89
Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions. Pharmacol Biochem Behav (2006) 0.89
Brain lipid metabolism, apolipoprotein E and the pathophysiology of Alzheimer's disease. Neuropharmacology (2010) 0.89
Neurosteroid biosynthetic pathways changes in prefrontal cortex in Alzheimer's disease. Neurobiol Aging (2009) 0.87
Neurosteroids: Cerebrospinal fluid levels for Alzheimer's disease and vascular dementia diagnostics. J Clin Endocrinol Metab (2003) 0.87
Beneficial effects of the sigma1 receptor agonists igmesine and dehydroepiandrosterone against learning impairments in rats prenatally exposed to cocaine. Neurotoxicol Teratol (2004) 0.85
Anti-apoptotic effects of allopregnanolone on P19 neurons. Eur J Neurosci (2006) 0.85
Allopregnanolone and dehydroepiandrosterone response to corticotropin-releasing factor in patients suffering from Alzheimer's disease and vascular dementia. Eur J Endocrinol (2000) 0.85
Traumatic brain injury as a risk factor for Alzheimer's disease. J Neurol Neurosurg Psychiatry (2004) 0.85
Allopregnanolone attenuates N-methyl-D-aspartate-induced excitotoxicity and apoptosis in the human NT2 cell line in culture. Neurosci Lett (2002) 0.85
Opposite effects of short- versus long-term administration of fluoxetine on the concentrations of neuroactive steroids in rat plasma and brain. Psychopharmacology (Berl) (2001) 0.84
Pregnenolone protects mouse hippocampal (HT-22) cells against glutamate and amyloid beta protein toxicity. Neurochem Res (2001) 0.84
Oxidative stress-mediated DHEA formation in Alzheimer's disease pathology. Neurobiol Aging (2002) 0.84
Dehydroepiandrosterone reduces expression and activity of BACE in NT2 neurons exposed to oxidative stress. Neurobiol Dis (2003) 0.83
Cerebrospinal fluid dehydroepiandrosterone levels are correlated with brain dehydroepiandrosterone levels, elevated in Alzheimer's disease, and related to neuropathological disease stage. J Clin Endocrinol Metab (2008) 0.83
A disturbance of late myelination as a trigger for Alzheimer's disease. Neurobiol Aging (2004) 0.83
Pathways of neurosteroid biosynthesis in cell lines from human brain: regulation of dehydroepiandrosterone formation by oxidative stress and beta-amyloid peptide. J Neurochem (2000) 0.82
Neurosteroid modulation of embryonic neuronal survival in vitro following anoxia. Brain Res (2000) 0.81
Neurosteroids block the increase in intracellular calcium level induced by Alzheimer’s β-amyloid protein in long-term cultured rat hippocampal neurons. Neuropsychiatr Dis Treat (2008) 0.80
Replacement with GABAergic steroid precursors restores the acute ethanol withdrawal profile in adrenalectomy/gonadectomy mice. Neuroscience (2010) 0.79
Excitatory neurosteroids attenuate apoptotic and excitotoxic cell death in primary cortical neurons. J Physiol Pharmacol (2008) 0.79
Dehydroepiandrosterone stimulates neurogenesis in mouse embryonal carcinoma cell- and human embryonic stem cell-derived neural progenitors and induces dopaminergic neurons. Stem Cells Dev (2010) 0.77
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA (2002) 6.72
Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med (2008) 5.34
Tissue-specific genetic control of splicing: implications for the study of complex traits. PLoS Biol (2008) 5.08
The Aging, Demographics, and Memory Study: study design and methods. Neuroepidemiology (2005) 4.44
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol (2008) 2.95
Treatment course with antidepressant therapy in late-life depression. Am J Psychiatry (2012) 2.94
Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. Arch Gen Psychiatry (2003) 2.70
A novel cerebral microangiopathy with endothelial cell atypia and multifocal white matter lesions: a direct mycoplasmal infection? J Neuropathol Exp Neurol (2007) 2.69
Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci U S A (2008) 2.59
Comparison of clinical and neuropathologic diagnoses of Alzheimer's disease in 3 epidemiologic samples. Alzheimers Dement (2006) 2.51
Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry (2008) 2.32
Reducing suicidal ideation in depressed older primary care patients. J Am Geriatr Soc (2006) 2.11
Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics (2008) 2.11
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care (2004) 1.99
Head injury in early adulthood and the lifetime risk of depression. Arch Gen Psychiatry (2002) 1.97
Psychiatric disease in the twenty-first century: The case for subcortical ischemic depression. Biol Psychiatry (2006) 1.94
Cognitive function in late life depression: relationships to depression severity, cerebrovascular risk factors and processing speed. Biol Psychiatry (2006) 1.92
Depression treatment preferences in older primary care patients. Gerontologist (2006) 1.92
Depressive symptoms in middle age and the development of later-life functional limitations: the long-term effect of depressive symptoms. J Am Geriatr Soc (2010) 1.88
Depressive symptoms and indicators of maternal health status during pregnancy. J Womens Health (Larchmt) (2007) 1.86
Premature ventricular complexes and the risk of incident stroke: the Atherosclerosis Risk In Communities (ARIC) Study. Stroke (2010) 1.82
Racial/ethnic variations in substance-related disorders among adolescents in the United States. Arch Gen Psychiatry (2011) 1.80
Aging-related diagnostic variations: need for diagnostic criteria appropriate for elderly psychiatric patients. Biol Psychiatry (2005) 1.77
Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry (2002) 1.75
Change is not always linear: the study of nonlinear and discontinuous patterns of change in psychotherapy. Clin Psychol Rev (2007) 1.73
Greater risk of dementia when spouse has dementia? The Cache County study. J Am Geriatr Soc (2010) 1.73
Dorsolateral prefrontal cortex and anterior cingulate cortex white matter alterations in late-life depression. Biol Psychiatry (2006) 1.73
Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial. Arch Gen Psychiatry (2010) 1.72
Genetic testing for Alzheimer's and long-term care insurance. Health Aff (Millwood) (2010) 1.67
The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database. Ann Surg Oncol (2012) 1.66
Incidence of dementia and cognitive impairment, not dementia in the United States. Ann Neurol (2011) 1.63
Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: the aging, demographics, and memory study. J Am Geriatr Soc (2010) 1.60
Minimally Invasive Versus Open Pancreaticoduodenectomy for Cancer: Practice Patterns and Short-term Outcomes Among 7061 Patients. Ann Surg (2015) 1.55
Late-life depression and microstructural abnormalities in dorsolateral prefrontal cortex white matter. Am J Psychiatry (2004) 1.55
Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. Arch Neurol (2005) 1.49
How do prescription opioid users differ from users of heroin or other drugs in psychopathology: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Addict Med (2011) 1.49
Identifying a national death index match. Am J Epidemiol (2009) 1.48
Prefrontal neuropsychological predictors of treatment remission in late-life depression. Neuropsychopharmacology (2004) 1.48
Vascular risk factors and cognitive decline among elderly male twins. Neurology (2006) 1.47
Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. J Clin Psychiatry (2005) 1.47
Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. Surgery (2007) 1.47
Clinical characteristics of magnetic resonance imaging-defined subcortical ischemic depression. Biol Psychiatry (2004) 1.46
Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev (2008) 1.46
Trends in emergency Medicaid expenditures for recent and undocumented immigrants. JAMA (2007) 1.46
White matter hyperintensity progression and late-life depression outcomes. Arch Gen Psychiatry (2003) 1.46
The persistence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry (2004) 1.46
Persistent mild cognitive impairment in geriatric depression. Int Psychogeriatr (2006) 1.45
Neurosteroids and self-reported pain in veterans who served in the U.S. Military after September 11, 2001. Pain Med (2010) 1.43
Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). Evid Rep Technol Assess (Full Rep) (2007) 1.42
Depressive state- and disease-related alterations in neural responses to affective and executive challenges in geriatric depression. Am J Psychiatry (2008) 1.42
A neural survival factor is a candidate oncogene in breast cancer. Proc Natl Acad Sci U S A (2003) 1.41
Influence of serotonin transporter promoter region polymorphisms on hippocampal volumes in late-life depression. Arch Gen Psychiatry (2005) 1.39
Body mass index and depressive symptoms in older adults: the moderating roles of race, sex, and socioeconomic status. Am J Geriatr Psychiatry (2007) 1.39
Greater MRI lesion volumes in elderly depressed subjects than in control subjects. Psychiatry Res (2005) 1.39
Protection from late life depression. Int Psychogeriatr (2009) 1.38
Genome-wide scan of copy number variation in late-onset Alzheimer's disease. J Alzheimers Dis (2010) 1.35
Serial MR imaging of volumes of hyperintense white matter lesions in elderly patients: correlation with vascular risk factors. AJR Am J Roentgenol (2003) 1.34
Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues. PLoS One (2009) 1.34
Association of trauma exposure with psychiatric morbidity in military veterans who have served since September 11, 2001. J Psychiatr Res (2009) 1.34
Midlife activity predicts risk of dementia in older male twin pairs. Alzheimers Dement (2008) 1.32
Hippocampal volume and antidepressant response in geriatric depression. Int J Geriatr Psychiatry (2002) 1.31
Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neurotrauma Pharmacology Workgroup. J Neurotrauma (2014) 1.31
Aging, gender, and the elderly adult brain: an examination of analytical strategies. Neurobiol Aging (2006) 1.30
Sporadic Pick's disease: a tauopathy characterized by a spectrum of pathological tau isoforms in gray and white matter. Ann Neurol (2002) 1.30
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology (2009) 1.28
An item response theory modeling of alcohol and marijuana dependences: a National Drug Abuse Treatment Clinical Trials Network study. J Stud Alcohol Drugs (2009) 1.27
Subtypes of nonmedical opioid users: results from the national epidemiologic survey on alcohol and related conditions. Drug Alcohol Depend (2010) 1.27
Epidemiology of late-life mental disorders. Clin Geriatr Med (2003) 1.26
Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther (2002) 1.25
Successful aging. Am J Geriatr Psychiatry (2006) 1.25
Racial differences in cognitive decline in a sample of community-dwelling older adults: the mediating role of education and literacy. Am J Geriatr Psychiatry (2005) 1.23
Population-based study of medical comorbidity in early dementia and "cognitive impairment, no dementia (CIND)": association with functional and cognitive impairment: The Cache County Study. Am J Geriatr Psychiatry (2005) 1.23
Application of assessing care of vulnerable elders-3 quality indicators to patients with advanced dementia and poor prognosis. J Am Geriatr Soc (2007) 1.22
Illicit and nonmedical drug use among older adults: a review. J Aging Health (2010) 1.22
Access to medical care among persons with psychotic and major affective disorders. Psychiatr Serv (2008) 1.22
Profiles of depressive symptoms in older adults diagnosed with major depression: latent cluster analysis. Am J Geriatr Psychiatry (2009) 1.21
Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord (2014) 1.21
After the collaborative is over: what sustains quality improvement initiatives in primary care practices? Jt Comm J Qual Patient Saf (2009) 1.20
A preliminary metabolomic analysis of older adults with and without depression. Int J Geriatr Psychiatry (2007) 1.19
Duke Twins Study of Memory in Aging in the NAS-NRC Twin Registry. Twin Res Hum Genet (2006) 1.19
Project among African-Americans to explore risks for schizophrenia (PAARTNERS): recruitment and assessment methods. Schizophr Res (2006) 1.19
The vascular depression subtype: evidence of internal validity. Biol Psychiatry (2008) 1.19
Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch Gen Psychiatry (2008) 1.18
The incidence of mental and behavioral disturbances in dementia: the cache county study. J Neuropsychiatry Clin Neurosci (2003) 1.18
Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias. J Neuropathol Exp Neurol (2005) 1.18
Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors. Genet Med (2007) 1.17